Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Stopped: REVIVE-FR Registry Withdrawn before enrolling Institut für Pharmakologie und Präventive MedizinNot specified NCT07885761
  2. Stopped: Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL Trial terminated Rita AssiPhase 2 NCT06484920
  3. Stopped: Tocilizumab, Ipilimumab, and Nivolumab · Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Trial terminated M.D. Anderson Cancer CenterPhase 2 NCT04940299
  4. Stopped: Unilateral M1 Anodal tDCS to Enhance Learning in a Gross Movement Videogame Task Trial terminated Indiana UniversityNot applicable NCT07447882
  5. Stopped: Low Intensity Focused Ultrasound for Binge Eating Disorder Trial terminated Ali RezaiNot applicable NCT06485687
  6. Stopped: Quality of Life After Hyperbaric Oxygen Therapy in Post-COVID Patients Trial status changed: Active, Not Recruiting → Withdrawn Rutger LalieuNot specified NCT06159309
  7. Stopped: Language Outcomes in Deaf Children Trial terminated The University of Tennessee, KnoxvilleNot specified NCT06724523
  8. Stopped: Use of Focused Ultrasound and DCE K-trans Imaging to Evaluate Permeability of the Blood-Brain Barrier Trial status changed: Enrolling by Invitation → Withdrawn Neurological Associates of West Los AngelesNot applicable NCT04063514
  9. Stopped: Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer Trial terminated Ludwig-Maximilians - University of MunichNot specified NCT04246203
  10. Stopped: Operator Radiation Exposure During Image-Guided Robotic-Assisted Bronchoscopy: A Multicenter Prospective Cohort Study Trial status changed: Recruiting → Withdrawn Memorial Sloan Kettering Cancer CenterNot specified NCT07318402
  11. Stopped: Non-invasive Cranial Electrical Stimulation for Mealtime Anxiety · Eating Disorders Trial terminated Rogers Behavioral HealthNot applicable NCT07017322
  12. Notable: Collection of Venous and Capillary Blood Samples Research, Optimization and Calibration of New Diagnostic Devices Enrollment reduced: 30000 → 12000 participants LumiraDx UK LimitedNot specified NCT07378514
  13. Notable: PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer Enrollment reduced: 534 → 130 participants Shanghai Gynecologic Oncology GroupPhase 2 NCT07931313
  14. Notable: Opioid-Free Anesthesia in Colorectal Surgery, 2025 (OFA-CRC-2025) Enrollment reduced: 200 → 100 participants Hospital Universitario La FePhase 1/2 NCT07771049
  15. Notable: Intravenous Versus Oral Treatment of the Main Acute Infections Enrollment reduced: 4000 → 2640 participants University of Southern DenmarkNot applicable NCT06715306
  16. Notable: Community Study to Increase Mammogram Screening Among Overdue Women Enrollment reduced: 15000 → 1500 participants National University Hospital, SingaporeNot applicable NCT07832396
  17. Notable: Intensive Weight Loss Intervention Versus Bariatric Surgery · Severe and Complex Obesity: the LightBAR Randomised Trial Enrollment reduced: 500 → 316 participants Carsten DirksenNot applicable NCT06309238
  18. Notable: Harnessing Artificial Intelligence for Diagnosing Androgenetic Alopecia: A Training and Validation Study Enrollment reduced: 400 → 240 participants Cairo UniversityNot specified NCT07294313
  19. Notable: 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream · Lichen Sclerosus Primary endpoint(s) modified LEO PharmaPhase 3 NCT07335588
  20. Notable: Garetosmab Versus Placebo Administered Intravenously (IV) · Fibrodysplasia Ossificans Progressiva (FOP) Results posted: Nov 17, 2026 Regeneron PharmaceuticalsPhase 3 NCT05394116
  21. Notable: Orally Administered JBI-802 · Essential Thrombocythemia (ET) and Polycythemia Vera (PV) With Thrombocytosis Primary and study completion dates pushed to Jan 30, 2031 Jubilant Therapeutics Inc.Phase 1/2 NCT07612280
  22. Notable: Trials of SHR-8203 Injection · Advanced Solid Tumors Recruitment opened Beijing Suncadia Pharmaceuticals Co., LtdPhase 1/2 NCT07769242
  23. Notable: HER3-DXd · Locally Advanced or Metastatic Solid Tumors Primary completion pushed from Sep 1, 2027 to Nov 19, 2030 Daiichi SankyoPhase 2 NCT06172478
  24. Notable: SHR-7590 in Chinese Healthy Participants and · Moderate-to-severe Inflammatory Bowel Disease Primary completion pushed from Jan 2027 to Mar 31, 2028 Guangdong Hengrui Pharmaceutical Co., LtdPhase 1 NCT07758101
  25. Notable: Comparative Self-collection for Cervical Cancer Screening Pivotal Study Primary endpoint(s) modified Mel Mont MedicalNot applicable NCT07758140